Eileen Crowley

Dr. Eileen Crowley completed her honours medical degree at the National University of Ireland and subspecialty training with the Royal College of Physicians, Ireland. Moving to SickKids, Toronto for fellowship training in Pediatric Gastroenterology, Hepatology and Nutrition and submitted her Master’s thesis entitled ‘Towards Personalized Care in Pediatric Inflammatory Bowel Disease’. She completed postdoctoral training and subspecialty Pediatric Inflammatory Bowel Disease training in the laboratory of Dr Aleixo Muise and received CIHR grant funding for supports.  She was co-supervised by Dr Anne Griffiths working on the Canadian (CIDsCaNN) IBD network.
Dr Crowley’s area of clinical specialty include pediatric IBD.  Her research interests include pediatric IBD, the genetics of IBD, therapeutic drug monitoring and precision medicine.  Her work has served to better delineate the genetic phenotype of children with IBD as well as optimizing response to therapy in this age group.
Dr Crowley works as a Pediatric Gastroenterologist at the Children’s Hospital, London Health Sciences, Ontario, as an Assistant Professor with Western University and Clinician Investigator in Pediatric IBD.  Dr Crowley intends to pursue further research in index development and clinical trials in Pediatric IBD.

Rohit Loomba

Dr. Rohit Loomba is a tenured Professor of Medicine in the Division of Gastroenterology, and Adjunct Professor in the Division of Epidemiology at the University of California, San Diego. He is a leading expert in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 25 clinical trials conducted worldwide. He holds two patents on non-invasive biomarkers of NAFLD and fibrosis.

His research is funded by the National Institutes of Health as a Principal Investigator currently leading three R01, a P01 and a U01 grant.

He is the Deputy Editor of hepatology, the official journal of the AASLD.

Dr. Loomba has published more than 250 manuscripts and has an H-index of 73. He is among the top 1% of the globally highly cited scientists across all fields in 2019 by Web of Science. He is an elected member of American Society of Clinical Investigation.

Evan S. Dellon

Evan S. Dellon, MD, MPH, is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine at Chapel Hill.

Dr. Dellon received his undergraduate degree from Brown University and his medical degree from the Johns Hopkins School of Medicine. He completed his internship and residency in Internal Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health.

Dr. Dellon joined the UNC faculty and the Center for Esophageal Diseases and Swallowing (CEDAS) in 2008, where his main clinical focus is on disorders of swallowing, and in particular eosinophilic esophagitis (EoE) and other eosinophilic gastrointestinal diseases (EGIDs). He became Director of CEDAS in 2014.

Dr. Dellon’s research interests span the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of EoE and EGIDs. The goal of his research is to improve the lives of patients with EoE/EGIDs by learning how to better diagnose, treat, and monitor the conditions. He is widely published in this area, with more than 265 peer-reviewed papers in the medical literature overall.

Dr. Dellon is also an Associate Editor for Clinical Gastroenterology and Hepatology. He collaborates with and advises Alimentiv Clinical Trials on studies related to EoE and EGIDs, including the areas of trial design, patient outcomes, and endpoint development.